HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Diastolic heart failure — Clinical Guidelines

Overview

Diastolic heart failure (DHF) is characterized by impaired ventricular relaxation and filling despite preserved systolic function, often associated with cardiac hypertrophy and increased myocardial stiffness 1.

Diagnosis

Echocardiography: Essential for assessing left ventricular hypertrophy and diastolic function parameters such as E/e' ratio 1 4.

Brain Natriuretic Peptide (BNP) Levels: Elevated BNP levels can aid in differentiating DHF from obstructive lung disease in patients with normal left ventricular systolic function 6.

E/e' Ratio: Used to grade diastolic dysfunction severity, with higher ratios indicating worse function 2.

Management

Spironolactone: Consider genotype-specific response; NR3C2 variants may influence efficacy 2.

ACE Inhibitors and ARBs: Different mechanisms in regulating ventricular fibrosis; both may be beneficial but mechanisms vary 5.

Rate Control: Managing tachycardia to prevent further impairment of stroke volume and diastolic function 4.

Special Populations

Genetic Considerations: NR3C2 and AGTR1 polymorphisms may influence treatment response and disease susceptibility 2 3.

Key Recommendations

Utilize echocardiography and BNP levels for accurate diagnosis of diastolic heart failure 1 6. (Evidence: Strong)

Consider genetic factors, particularly NR3C2 variants, when prescribing spironolactone to optimize response 2. (Evidence: Moderate)

Implement rate control strategies to mitigate the adverse effects of tachycardia on stroke volume in patients with DHF 4. (Evidence: Moderate)

References

1 Dewan S, Witayavanitkul N, Kumar M, Mayer BJ, Betancourt L, Cazorla O et al.. Depressed myocardial cross-bridge cycling kinetics in a female guinea pig model of diastolic heart failure. The Journal of general physiology 2023. link 2 Dumeny L, Vardeny O, Edelmann F, Pieske B, Duarte JD, Cavallari LH. NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial. Pharmacotherapy 2021. link 3 Wu CK, Tsai CT, Chang YC, Luo JL, Wang YC, Hwang JJ et al.. Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. Journal of hypertension 2009. link 4 Sohn DW, Kim HK, Park JS, Chang HJ, Kim YJ, Zo ZH et al.. Hemodynamic effects of tachycardia in patients with relaxation abnormality: abnormal stroke volume response as an overlooked mechanism of dyspnea associated with tachycardia in diastolic heart failure. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2007. link 5 Yamamoto K, Mano T, Yoshida J, Sakata Y, Nishikawa N, Nishio M et al.. ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. Journal of hypertension 2005. link 6 Cabanes L, Richaud-Thiriez B, Fulla Y, Heloire F, Vuillemard C, Weber S et al.. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001. link

Diastolic heart failure